Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Suwarti S.; Lazarus G.; Zanjabila S.; Sinto R.; Fransiska F.; Deborah T.; Oktavia D.; Junaidah J.; Santayana S.; Surendra H.; Yuliana J.; Pardosi H.; Nuraeni N.; Soebianto S.; Susilowati N.D.; Subekti D.; Pradipta A.; Baird J.K.; Tan L.V.; Dunachie S.; Shankar A.H.; Nelwan E.J.; Hamers R.L.; Anh N.T.; Hong N.T.T.; Truc T.H.C.; Ny N.T.H.; Han D.D.K.; Thanh L.K.; Nguyet L.A.; Thuy C.T.; Nhu L.N.T.; Thanh T.T.; Yen L.M.; Hang V.T.; Kieu P.T.; Hoang V.T.; Thao N.T.; Chambers M.; Thanh V.D.; Hoang T.C.; Thwaites C.L.; Thwaites G.; van Doorn H.R.; Tung T.S.; Mongkolsapaya J.; Screaton G.; Dijokaite-Guraliuc A.; Das R.; Liu C.; Supasa P.; Selvaraj M.; Klenerman P.; Jones E.Y.; Stuart D.I.; Kronsteiner-Dobramysl B.; Zewdie M.; Abraham P.; Hill J.; Tayipto Y.; Paramita I.; Lin-Fa W.; Wah T.C.; Chee Y.W.; Lee L.B.; Suwarti; Simarmata E.; Dien R.; Dejnirattisai W.; Chantima W.; Chantratita N.; Poolchanuan P.; Tiacharoen V.; Dulsuk A.; Iamsirithaworn S.; Day N.; Cheah P.Y.; Poomchaichote T.; Boonthaworn K.; Ngoc N.M.; Grifoni A.; Sette A.
Suwarti, Suwarti (55550498500); Lazarus, Gilbert (57214599425); Zanjabila, Sabighoh (57211797750); Sinto, Robert (36099377100); Fransiska, Fransiska (58627520400); Deborah, Theresia (59246936400); Oktavia, Dwi (57219415909); Junaidah, Junaidah (59246966400); Santayana, Santayana (59246859900); Surendra, Henry (57192694199); Yuliana, Jeng (59246952600); Pardosi, Herlina (59246966500); Nuraeni, Nunung (58487385000); Soebianto, Saraswati (6506164276); Susilowati, Novi Dwi (59246936500); Subekti, De
55550498500; 57214599425; 57211797750; 36099377100; 58627520400; 59246936400; 57219415909; 59246966400; 59246859900; 57192694199; 59246952600; 59246966500; 58487385000; 6506164276; 59246936500; 6603632507; 57216644806; 15921267800; 58806053300; 57537262900; 7005442634; 14527452900; 23034345900; 57212368679; 57221370386; 58853091400; 58245332000; 57204713782; 57220088404; 55902545400; 35273734000; 15837969100; 7004531564; 12772247500; 16165972000; 58046943100; 58475243600; 16318152600; 57216076926; 58881090000; 58880946300; 13606172400; 6603796838; 59172638600; 57195563473; 6602451584; 7003284408; 57740234800; 57777499500; 57203978566; 57189988042; 57224852556; 57216302662; 7404236867; 56377639700; 57191896915; 26322857700; 57794253100; 57190211625; 57326371500; 59248793500; 59249546500; 57251894800; 58881369700; 58880657400; 58107161900; 58881514800; 57233234500; 6505510584; 55266427300; 57189051906; 57217081009; 57999197000; 57193499585; 8937073300; 57708887000; 55748909600; 57218252898; 57195319753; 25626478900; 55425663600; 35418504700
Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers
2024
BMC Infectious Diseases
24
1
768
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85200433103&doi=10.1186%2fs12879-024-09644-y&partnerID=40&md5=5c3abda543c836dd8ec371deb0a22168
Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Infectious Disease and Immunology Research Cluster, Indonesian Medical Education and Research Institute, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; St Carolus Hospital, Jakarta, Indonesia; Jakarta Health Office, Ministry of Health Republic of Indonesia, Jakarta, Indonesia; Monash University, Tangerang, Indonesia; Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom; Genomik Solidaritas Indonesia Lab, Jakarta, Indonesia; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
Suwarti S., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Infectious Disease and Immunology Research Cluster, Indonesian Medical Education and Research Institute, Jakarta, Indonesia; Lazarus G., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Zanjabila S., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Sinto R., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Division of Tropical and Infectious Diseases, Department of Internal Medicine, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia, St Carolus Hospital, Jakarta, Indonesia; Fransiska F., St Carolus Hospital, Jakarta, Indonesia; Deborah T., St Carolus Hospital, Jakarta, Indonesia; Oktavia D., Jakarta Health Office, Ministry of Health Republic of Indonesia, Jakarta, Indonesia; Junaidah J., Jakarta Health Office, Ministry of Health Republic of Indonesia, Jakarta, Indonesia; Santayana S., Jakarta Health Office, Ministry of Health Republic of Indonesia, Jakarta, Indonesia; Surendra H., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Monash University, Tangerang, Indonesia; Yuliana J., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Pardosi H., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Nuraeni N., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Soebianto S., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Susilowati N.D., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Subekti D., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Pradipta A., Genomik Solidaritas Indonesia Lab, Jakarta, Indonesia, Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Baird J.K., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom; Tan L.V., Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom, Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; Dunachie S., Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Shankar A.H., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom; Nelwan E.J., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Division of Tropical and Infectious Diseases, Department of Internal Medicine, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Hamers R.L., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom; Anh N.T.; Hong N.T.T.; Truc T.H.C.; Ny N.T.H.; Han D.D.K.; Thanh L.K.; Nguyet L.A.; Thuy C.T.; Nhu L.N.T.; Thanh T.T.; Yen L.M.; Hang V.T.; Kieu P.T.; Hoang V.T.; Thao N.T.; Chambers M.; Thanh V.D.; Hoang T.C.; Thwaites C.L.; Thwaites G.; van Doorn H.R.; Tung T.S.; Mongkolsapaya J.; Screaton G.; Dijokaite-Guraliuc A.; Das R.; Liu C.; Supasa P.; Selvaraj M.; Klenerman P.; Jones E.Y.; Stuart D.I.; Kronsteiner-Dobramysl B.; Zewdie M.; Abraham P.; Hill J.; Tayipto Y.; Paramita I.; Lin-Fa W.; Wah T.C.; Chee Y.W.; Lee L.B.; Suwarti; Simarmata E.; Dien R.; Dejnirattisai W.; Chantima W.; Chantratita N.; Poolchanuan P.; Tiacharoen V.; Dulsuk A.; Iamsirithaworn S.; Day N.; Cheah P.Y.; Poomchaichote T.; Boonthaworn K.; Ngoc N.M.; Grifoni A.; Sette A.
Background: Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited. This study evaluated the sequential effects of prior infection, heterologous boosting with mRNA-1273 (Moderna), and the occurrence of Omicron vaccine-breakthrough infection (VBI) thereafter. Methods: We evaluated anti-spike IgG (Abbott) and neutralising (cPASS/GenScript) antibody (nAb) titers up to one year after mRNA-1273 boost in two-dose-CoronaVac-primed Indonesian healthcare workers (August 2021-August 2022). We used linear mixed modeling to estimate the rate of change in antibody levels, and logistic regression to examine associations between antibody levels and VBI. Results: Of 138 participants, 52 (37.7%) had a prior infection and 78 (56.5%) received an mRNA-1273 booster. After two-dose CoronaVac, antibody titers had significantly declined within 180 days, irrespective of prior infection. After mRNA-1273 booster, anti-spike IgG (1.47% decline/day) and Omicron B.1.1.529/BA.2 nAbs declined between day 28–90, and IgG titers plateaued between day 90–360. During the BA.1/BA.2 wave (February–March 2022), 34.6% (27/78) of individuals experienced a VBI (median 181 days after mRNA-1273), although none developed severe illness. VBI was associated with low pre-VBI anti-spike IgG and B.1.1.529/BA.2 nAbs, which were restored post-VBI. Conclusions: mRNA-1273 booster after two-dose CoronaVac did not prevent BA.1/BA.2 VBI. Periodic vaccine boosters may be warranted against emerging SARS-CoV-2 variants. © The Author(s) 2024.
CoronaVac; COVID-19; Humoral immunity; mRNA-1273; SARS-CoV-2
2019-nCoV Vaccine mRNA-1273; Adult; Antibodies, Neutralizing; Antibodies, Viral; Breakthrough Infections; COVID-19; COVID-19 breakthrough infections; COVID-19 Vaccines; Female; Health Personnel; Humans; Immunization, Secondary; Immunoglobulin G; Indonesia; Male; Middle Aged; SARS-CoV-2; SARS-CoV-2 variants; Spike Glycoprotein, Coronavirus; Vaccination; Vaccines, Inactivated; coronavac; elasomeran; neutralizing antibody; SARS-CoV-2 antibody; coronavirus spike glycoprotein; elasomeran; immunoglobulin G; inactivated vaccine; neutralizing antibody; SARS-CoV-2 vaccine; virus antibody; adult; antibody response; antibody titer; Article; breakthrough infection; chemiluminescent microparticle immunoassay; cohort analysis; controlled study; enzyme linked immunosorbent assay; female; human; humoral i
BioMed Central Ltd
14712334
39090537
Article
Q1
1031
4223

Unit Riset FKUI/Medical Research Unit
Gedung IMERI Tower Riset lt. 9, Jl. Salemba Raya No. 6, Jakarta Pusat, 10430
Telp. : +62 21 29189160 (ext. 201912)
E-mail : manajer.riset.fkui1@gmail.com